Thymosin α-1 / Ta1
Reboot the immune code safely.
SC injection — 1.6 mg weekly SC injection (athlete protocol); 1.6 mg 2–3x/week in immune boost protocols; dosing per physician based on immune labs
What It Is
Thymosin α-1 (Ta1) is a thymus-derived peptide that boosts T-cell maturation and restores immune balance. It is used to enhance immune surveillance in chronic infections and cancer.
Mechanism
Ta1 boosts T-cell maturation and restores immune balance — used to enhance immune surveillance in chronic infections and cancer. It is given to cancer patients as an adjunct (improves response to chemo by immune enhancement), or to those with HBV/HCV, etc. Emer's RECODEX uses Ta1 in RE:VIVE™ phase to "reboot immune code" safely. Studies show Ta1 can improve vaccine responses.
How Dr. Emer Uses It
In Emer's practice, Ta1 is used in the RE:VIVE phase (immediate recovery phase) alongside BPC-157 and Prime IVs that "code" for healing and immune defense. In the "30-Year-Old Male, Athlete/Biohacker Archetype" case, Thymosin α-1 (1.6 mg weekly) is given to keep the immune system strong under heavy training (prevent overtraining syndrome). For oncology integrative protocols, Ta1 injections improve outcomes and lower infection risk during chemo. Emer's Wolverine Stack may include Ta1 in patients doing intense recovery to prevent illness downtime.
Key Benefits
- ✓Boosts T-cell maturation and restores immune balance
- ✓Enhances immune surveillance in chronic infections (HBV/HCV)
- ✓Improves response to chemotherapy by immune enhancement
- ✓Prevents overtraining syndrome in competitive athletes by modulating immunity
- ✓Improves vaccine responses (studies confirm)
- ✓Reduces chemo-induced immune suppression as cancer adjunct therapy
Pairs Well With
Used In Programs
Safety & Considerations
Sides minimal: some injection site redness. Studies show Ta1 can improve vaccine responses and works with oncologic therapies (makes immune checkpoint inhibitors work better, for example). Generally very well tolerated. Side effects minimal; some injection site redness. Experimental in the US but has regulatory approval in some countries (e.g. in Italy as Zadaxin for hepatitis). Off-label in the US.
Begin Your RECODEX™ Protocol
All peptide therapies are prescribed under direct medical supervision.
Book a Consultation
